CADM1 and prostate cancer: Specifically, it intensifies the progression of lung adenocarcinoma by targeting CADM1, promotes the progression of prostate cancer by targeting GRIM-19, and suppresses the proliferation and invasion of osteosarcoma by targeting STMN1 [48,49].